실험실 정보 관리 시스템 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The laboratory information management system market size reached USD 595.62 million in 2025 and is projected to climb to USD 946.24 million by 2030, reflecting a 9.7% CAGR.

This momentum springs from sustained digitalization across research and quality-driven laboratories, where end-to-end data traceability now sits at the core of regulatory inspections. Growth also benefits from artificial-intelligence workflows that convert raw assay data into decision-ready insights, freeing scientists from repetitive curation tasks. Heightened demand for remote sample oversight, born out of pandemic-era decentralization, keeps investment focused on platforms that offer mobile accessioning, automated chain-of-custody, and real-time analytics. Providers that bundle LIMS, scientific data management, and electronic laboratory notebooks into unified cloud offerings continue to widen adoption by removing silo-bound workflows. Finally, the fast-rising volume of genomic, biobanking, and cell-therapy samples reinforces the value proposition of systems that secure data integrity from collection to long-term archival.

Global Laboratory Information Management System Market Trends and Insights

Rapid Growth of Pharmaceutical & Biotech R&D Pipeline

Global drug-development programs now exceed 20,000 active candidates, a figure 38% higher than in 2020. Each new molecule multiplies laboratory data volumes, intensifying the need for scalable LIMS that automate contextualization and audit trails. Platforms equipped with AI-driven outlier detection are shortening data-review cycles by 43% in quality-control labs, freeing analyst capacity and accelerating batch release . Seamless integration of LIMS with electronic notebooks and scientific data hubs breaks down informational barriers, letting multidisciplinary teams interrogate datasets from discovery through scale-up without manual exports. This capability speeds go/no-go decisions and supports adaptive trial designs that cut overall development timelines.

Growing Demand for Biobanking

More than 70% of precision-medicine programs depend on biorepositories that safeguard consented samples across decades. Modern systems pair IoT-enabled freezer monitoring with event-driven alerts that avert temperature excursions. Barcode-centred inventory in leading institutions has trimmed retrieval times by 67% while eliminating count discrepancies .Blockchain-anchored chain-of-custody is entering production environments, providing immutable provenance logs critical for gene-therapy samples whose usage rights link directly to donor consent. These advanced features elevate LIMS from passive record-keepers to proactive guardians of specimen integrity.

High Total Cost of Ownership and Prolonged Validation

Enterprise deployments may exceed USD 1 million in license fees and require validation periods that stretch 6-9 months, delaying return on investment. A Vermont public-health lab documented a USD 1.7 million spend covering customization and maintenance. Subscription-priced SaaS options mitigate capital outlay yet still confront conservative quality-assurance teams reluctant to outsource infrastructure. Vendors are countering with prevalidated templates that shorten qualification cycles and bundled managed-services contracts that cap lifetime costs.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Enabled Genomic-Testing Workflows
2. Rapid Expansion of Decentralized Clinical Trials
3. Precision-Agriculture Soil-Microbiome Analysis
4. Data Security and Sovereignty Concerns
5. Scarce Bioinformatics Talent Slowing Advanced LIMS Uptake

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The laboratory information management system market recorded services commanding 52% revenue in 2024, underscoring laboratories' reliance on external expertise for validation, integration, and continuous refinement. These engagements often extend for multiple years, ensuring workflows evolve with regulatory updates and new instrumentation. In parallel, demand for cloud-native subscriptions is accelerating at 10.8% CAGR, encouraged by elastic scaling and automatic feature rollouts that avoid interruption to bench activities. Service providers are broadening portfolios to include validation-as-a-service and AI-model stewardship, giving clients turnkey access to capabilities otherwise constrained by talent gaps. This pattern illustrates how software utility is maximized only when paired with strategic domain guidance that aligns system configuration with evolving scientific aims.

Second-generation managed-service models increasingly assume responsibility for algorithm training and performance monitoring, creating recurring revenue streams that mirror the software-as-a-service mindset. Laboratories appreciate predictable expenditure and quicker time-to-value, especially when tackling novel modalities such as single-cell sequencing. Several vendors now embed outcome-based pricing that links service fees to quantified efficiency gains, a structure that encourages ongoing optimization rather than one-off implementation milestones. The laboratory information management system market therefore rewards suppliers able to combine configurable platforms with consultative depth that navigates both technology and compliance landscapes.

On-premise systems retained 55% of 2024 revenue because heavily regulated facilities favour direct control over infrastructure, validation scripts, and data-access policies. However, the cloud cohort is forecast to grow 10.2% CAGR as laboratories seek remote accessibility and lighter IT overhead. Hybrid designs that mirror familiar workstation UIs while storing data in sovereign clouds provide an acceptable bridge, satisfying auditors yet permitting elastic compute for analytics bursts. For smaller labs, cloud subscriptions slash capital outlay and compress deployment into weeks, democratizing best-practice workflows once confined to big-pharma budgets.

Operational experience gained during pandemic lockdowns demonstrated the resilience of browser-based access, prompting even conservative quality leaders to pilot SaaS sandboxes for non-GxP functions. As confidence builds, production workloads migrate, often beginning with stability studies or environmental monitoring modules before moving critical release assays. Over time, the laboratory information management system market is expected to show a converged architecture in which edge appliances handle instrument ingestion while regulatory-grade copies reside in regional cloud vaults, ensuring both latency control and compliance.

The Report Covers LIMS Vendors and the Market is Segmented by Component (Software and Services), Product Type (Broad-Based / Multi-Purpose LIMS, and More), Deployment Model (On-Premise, Web-Hosted, and Cloud-Based), Enterprise Size (Large Laboratory Networks, and More, Application (Drug Discovery & Pre-Clinical, Clinical Trials & Bioanalysis, and More), End User (Pharmaceutical & Biotech Companies, and More), and Geography

Geography Analysis

North America generated the largest share of laboratory information management system market revenue in 2024 at 35%, underpinned by extensive pharmaceutical R&D investment and a mature ecosystem of informatics vendors and integrators. Regulatory scrutiny from agencies such as the FDA prioritizes data integrity, pressing laboratories to maintain comprehensive audit trails and electronic signatures that LIMS deliver. Integration of AI for proactive quality monitoring is progressing rapidly, with leading manufacturers deploying predictive analytics that flag potential deviations before release-blocking events occur. High adoption of precision medicine, coupled with reimbursement pathways for genomic testing, further stimulates demand for platforms that capture sequencing data and patient consents within unified records.

Asia-Pacific registers the fastest trajectory, with an 11.3% CAGR projected through 2030. Regional expansion of vaccine and biologics manufacturing in China and India is paired with government incentives encouraging digital transformation of laboratory infrastructure. Contract research organizations operating in Singapore and South Korea deploy LIMS to demonstrate Good Laboratory Practice compliance, winning contracts from multinational sponsors seeking cost-effective yet quality-assured partners. Japan's national genomics initiatives integrate privacy-centric consent workflows, making LIMS central to ethical data stewardship. Meanwhile, Australian agri-tech stakeholders adopt soil-microbiome informatics in support of sustainable-farming imperatives, extending LIMS penetration beyond healthcare.

Europe maintains a sizable footprint driven by stringent data-protection regulations and a robust biopharma manufacturing base. GDPR influences system design, mandating region-locked data residency and granular consent management. Pharmaceutical laboratories integrate LIMS with Qualified Person release systems, ensuring traceability from raw material intake through final product certification. The continent's extensive biobanking network leverages specialized modules for longitudinal sample tracking and cross-border data exchange within pan-European research consortia. Post-Brexit divergence of U.K. regulatory codes triggers configuration projects to meet Medicines and Healthcare products Regulatory Agency guidelines, generating fresh service revenue for implementation partners.

1. Thermo Fisher Scientific
2. LabWare
3. LabVantage Solutions
4. Abbott Informatics (STARLIMS)
5. Autoscribe Informatics
6. Accelerated Technology Laboratories
7. Genologics (Illumina Inc.)
8. LabLynx
9. Siemens Healthineers
10. Dassault Systemes SE (BIOVIA)
11. Agilent Technologies
12. Waters Corporation (NuGenesis)
13. PerkinElmer Inc. (Signals Notebook)
14. Cerner Corp. (Oracle Health)
15. Clinisys Group Ltd.
16. Sunquest Information Systems Inc.
17. Blomesystem GmbH
18. Sapio Sciences LLC
19. Benchling Inc.
20. Ocimum Biosolutions Ltd.
21. Computing Solutions Inc.
22. Labworks

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rapid Growth of Pharmaceutical & Biotech R&D Pipeline
  • 4.2.2 Growing Demand for Biobanking
  • 4.2.3 AI-Enabled Genomic-Testing Workflows Boosting LIMS Demand in Precision Medicine Labs
  • 4.2.4 Rising adoption of contract research and manufacturing outsourcing
  • 4.2.5 Rapid Expansion of Decentralized Clinical Trials Requiring Remote Sample Logistics
  • 4.2.6 Precision-Agriculture Soil-Microbiome Analysis Labs Deploying LIMS
• 4.3 Market Restraints
  • 4.3.1 High Total Cost of Ownership and Prolonged Validation
  • 4.3.2 Interoperability challenges with legacy laboratory information systems and heterogeneous instrument interfaces.
  • 4.3.3 Data Security and Sovereignty Concerns
  • 4.3.4 Scarce Bioinformatics Talent Slowing Advanced LIMS Uptake
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory & Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Component
  • 5.1.1 Software
  • 5.1.2 Services
• 5.2 By Product Type
  • 5.2.1 Broad-based / Multi-purpose LIMS
  • 5.2.2 Pharma-specific LIMS
• 5.3 By Deployment Model
  • 5.3.1 On-premise
  • 5.3.2 Web-hosted
  • 5.3.3 Cloud-based
• 5.4 By Enterprise Size
  • 5.4.1 Large Laboratory Networks
  • 5.4.2 Small & Medium-sized Laboratories
• 5.5 By Application
  • 5.5.1 Drug Discovery & Pre-clinical
  • 5.5.2 Clinical Trials & Bioanalysis
  • 5.5.3 Manufacturing Quality Control (QC)
  • 5.5.4 Biobanking & Sample Tracking
• 5.6 By End User
  • 5.6.1 Pharmaceutical & Biotech Companies
  • 5.6.2 Contract Research / Development & Manufacturing Orgs (CROs / CDMOs)
  • 5.6.3 Academic Medical & Research Institutes
  • 5.6.4 Hospital & Clinical Diagnostic Labs
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 South Korea
    • 5.7.3.5 Australia
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company profiles ((includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Thermo Fisher Scientific Inc.
  • 6.4.2 LabWare Inc.
  • 6.4.3 LabVantage Solutions Inc.
  • 6.4.4 Abbott Informatics (STARLIMS)
  • 6.4.5 Autoscribe Informatics
  • 6.4.6 Accelerated Technology Laboratories Inc.
  • 6.4.7 Genologics (Illumina Inc.)
  • 6.4.8 LabLynx Inc.
  • 6.4.9 Siemens Healthineers AG
  • 6.4.10 Dassault Systemes SE (BIOVIA)
  • 6.4.11 Agilent Technologies Inc.
  • 6.4.12 Waters Corporation (NuGenesis)
  • 6.4.13 PerkinElmer Inc. (Signals Notebook)
  • 6.4.14 Cerner Corp. (Oracle Health)
  • 6.4.15 Clinisys Group Ltd.
  • 6.4.16 Sunquest Information Systems Inc.
  • 6.4.17 Blomesystem GmbH
  • 6.4.18 Sapio Sciences LLC
  • 6.4.19 Benchling Inc.
  • 6.4.20 Ocimum Biosolutions Ltd.
  • 6.4.21 Computing Solutions Inc.
  • 6.4.22 Labworks LLC

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment